Showing results (141-150 of 366) with videos related to
Sort By:
Pageof 37
The Lancet. Oncology|October 28, 2017
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trialAlice T Shaw, Enriqueta Felip, Todd M Bauer, et al.Genome Biology|March 3, 2017
Single-cell transcriptome conservation in cryopreserved cells and tissuesAmy Guillaumet-Adkins, Gustavo Rodríguez-Esteban, Elisabetta Mereu, et al.Clinical Drug Investigation|July 31, 2024
Expert Consensus on the Management of Adverse Events of Lorlatinib in the Treatment of ALK+ Advanced Non-small Cell Lung CancerEdurne Arriola, Javier de Castro, Rosario García-Campelo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 21, 2023
Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)Ernest Nadal, Delvys Rodríguez-Abreu, Marta Simó, et al.European Journal of Cancer (Oxford, England : 1990)|January 18, 2019
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancerBenjamin P Levy, Giuseppe Giaccone, Benjamin Besse, et al.The Journal of Experimental Medicine|September 28, 2022
DSTYK inhibition increases the sensitivity of lung cancer cells to T cell-mediated cytotoxicityKarmele Valencia, Mirari Echepare, Álvaro Teijeira, et al.Cancer|January 12, 2021
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 studyKeunchil Park, Pasi A Jӓnne, Dong-Wan Kim, et al.The Lancet. Respiratory Medicine|January 20, 2020
Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 studyDaniel S-W Tan, Natasha B Leighl, Gregory J Riely, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2022
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part II: prostate cancer and colorectal cancerAntonio José Conde-Moreno, Aránzazu González-Del-Alba, Fernando López-Campos, et al.Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|December 16, 2022
Unravelling oligometastatic disease from the perspective of radiation and medical oncology. Part I: non-small cell lung cancer and breast cancerAurora Rodríguez Pérez, Enriqueta Felip Font, Rodolfo Chicas-Sett, et al.Pageof 37